

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11701495/publications.pdf>

Version: 2024-02-01

376  
papers

155,000  
citations

764

119  
h-index

90

357  
g-index

380  
all docs

380  
docs citations

380  
times ranked

152584  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of pharmacological and nonpharmacological treatments for chronic noncancer pain among people using opioids: a longitudinal cohort study. <i>Pain</i> , 2022, 163, 1049-1059.	2.0	2
2	Comorbidity between mood and substance-related disorders: A systematic review and meta-analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 757-770.	1.3	14
3	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	1.6	22
4	Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. <i>Addiction</i> , 2022, 117, 1338-1352.	1.7	11
5	Exposure to childhood trauma increases risk of opioid use disorder among people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109199.	1.6	9
6	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e136-e145.	4.7	14
7	Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study. <i>Lancet Psychiatry</i> , the, 2022, 9, 151-159.	3.7	6
8	Mood and Anxiety Symptoms in Persons Taking Prescription Opioids: A Systematic Review with Meta-Analyses of Longitudinal Studies. <i>Pain Medicine</i> , 2022, 23, 1442-1456.	0.9	14
9	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	1.1	7
10	State-Level Prevalence and Associates of Opioid Dependence in the USA. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3825.	1.2	4
11	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109464.	1.6	7
12	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. <i>International Journal of Drug Policy</i> , 2022, 105, 103708.	1.6	2
13	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109494.	1.6	12
14	Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109543.	1.6	6
15	Trends in opioid analgesic utilisation among people with a history of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109548.	1.6	3
16	Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109551.	1.6	31
17	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021, 49, 1774-1775.	0.9	10
18	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 1664-1676.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001â€“2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108354.	1.6	5
20	All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 725-742.	1.7	21
21	Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108459.	1.6	26
22	Trends in cocaine use, markets and harms in Australia, 2003â€“2019. <i>Drug and Alcohol Review</i> , 2021, 40, 946-956.	1.1	15
23	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. <i>Exploration of Medicine</i> , 2021, 2, 60-73.	1.5	6
24	The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas. <i>Journal of Substance Abuse Treatment</i> , 2021, 121, 108189.	1.5	12
25	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001â€“2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	1.6	10
26	Variations in Long-term Opioid Therapy Definitions: A Systematic Review of Observational Studies Using Routinely Collected Data (2000â€“2019). <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3706-3720.	1.1	5
27	International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2021, 162, S117-S124.	2.0	33
28	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021, 4, e213059.	2.8	4
29	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. <i>Lancet Psychiatry</i> , 2021, 8, 301-309.	3.7	20
30	Estimating the risk of suicide associated with mental disorders: A systematic review and meta-regression analysis. <i>Journal of Psychiatric Research</i> , 2021, 137, 242-249.	1.5	76
31	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. <i>Addiction</i> , 2021, 116, 3139-3152.	1.7	14
32	Alcohol use among young Australian adults in Mayâ€“June 2020 during the COVID-19 pandemic: a prospective cohort study. <i>Addiction</i> , 2021, 116, 3398-3407.	1.7	34
33	Big data and predictive modelling for the opioid crisis: existing research and future potential. <i>The Lancet Digital Health</i> , 2021, 3, e397-e407.	5.9	21
34	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. <i>JAMA Psychiatry</i> , 2021, 78, 979.	6.0	244
35	Unintentional and intentional drug poisoning deaths, Australia, 2012â€“2016: Drug pattern profile and demographic characteristics. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109112.	1.6	6
36	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990â€“2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV</i> , 2021, 8, e633-e651.	2.1	56

#	ARTICLE	IF	CITATIONS
37	Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109091.	1.6	4
38	Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109050.	1.6	9
39	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3092-3104.	1.1	9
40	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e69-e78.	2.9	43
41	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e107-e118.	2.9	39
42	General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. <i>Pain</i> , 2021, 162, S80-S96.	2.0	32
43	Perceived helpfulness of treatment for alcohol use disorders: Findings from the World Mental Health Surveys. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109158.	1.6	3
44	Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e70.	1.8	3
45	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88.	0.9	8
46	The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys. <i>Addictive Behaviors</i> , 2020, 102, 106128.	1.7	108
47	Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. <i>American Journal of Public Health</i> , 2020, 110, 45-50.	1.5	44
48	Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	1.7	88
49	Opioid use disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 3.	18.1	278
50	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. <i>JAMA Psychiatry</i> , 2020, 77, 493.	6.0	83
51	Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , 2020, 39, 128-134.	1.1	7
52	Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107697.	1.6	10
53	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2020, 8, e76-e91.	2.9	19
54	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107793.	1.6	44

#	ARTICLE	IF	CITATIONS
55	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	1.7	46
56	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 76, 102619.	1.6	21
57	Parental supply of sips and whole drinks of alcohol to adolescents and associations with binge drinking and alcohol-related harms: A prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108204.	1.6	16
58	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 84, 102866.	1.6	17
59	A large-scale genome-wide association study meta-analysis of cannabis use disorder. <i>Lancet Psychiatry</i> , 2020, 7, 1032-1045.	3.7	200
60	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , 2020, 396, 1204-1222.	6.3	7,664
61	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , 2020, 396, 1223-1249.	6.3	3,928
62	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592.	3.2	16
63	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108135.	1.6	20
64	All-Cause and Overdose Mortality Risk Among People Prescribed Opioids: A Systematic Review and Meta-analysis. <i>Pain Medicine</i> , 2020, 21, 3700-3711.	0.9	10
65	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia. <i>Journal of Psychiatric Research</i> , 2020, 130, 435-440.	1.5	15
66	Generational trends in US opioid-overdose deaths. <i>Nature Medicine</i> , 2020, 26, 651-652.	15.2	8
67	The association between parental supply of alcohol and supply from other sources to young people: a prospective cohort. <i>Addiction</i> , 2020, 115, 2140-2147.	1.7	4
68	Rates, characteristics and manner of cannabis-related deaths in Australia 2000–2018. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108028.	1.6	14
69	The overall effect of parental supply of alcohol across adolescence on alcohol-related harms in early adulthood—a prospective cohort study. <i>Addiction</i> , 2020, 115, 1833-1843.	1.7	10
70	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107899.	1.6	3
71	Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. <i>Molecular Psychiatry</i> , 2020, 25, 1673-1687.	4.1	82
72	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. <i>International Journal of Drug Policy</i> , 2020, 77, 102656.	1.6	20

#	ARTICLE	IF	CITATIONS
73	Association between Mental Disorders and Subsequent Medical Conditions. <i>New England Journal of Medicine</i> , 2020, 382, 1721-1731.	13.9	258
74	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	1.7	50
75	Adolescent cannabis use disorders. , 2020, , 111-135.		2
76	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	1.2	44
77	Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2020, Publish Ahead of Print, S110-S116.	2.0	10
78	The Mortality After Release from Incarceration Consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis. <i>International Journal of Population Data Science</i> , 2020, 5, 1145.	0.1	9
79	Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. <i>Addiction</i> , 2019, 114, 534-552.	1.7	36
80	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	1.7	178
81	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769.	0.9	9
82	Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2019, 24, 1868-1883.	4.1	215
83	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1388-1403.	1.0	11
84	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 73, 172-184.	1.6	67
85	The epidemiology of drug use disorders cross-nationally: Findings from the WHO's World Mental Health Surveys. <i>International Journal of Drug Policy</i> , 2019, 71, 103-112.	1.6	45
86	Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. <i>Lancet, The</i> , 2019, 394, 1580-1590.	6.3	224
87	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet, The</i> , 2019, 394, 1560-1579.	6.3	404
88	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	6.3	169
89	New psychoactive substances: challenges for drug surveillance, control, and public health responses. <i>Lancet, The</i> , 2019, 394, 1668-1684.	6.3	195
90	Strategies to reduce drug-related harm: responding to the evidence base. <i>Lancet, The</i> , 2019, 394, 1490-1493.	6.3	15

#	ARTICLE	IF	CITATIONS
91	Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107533.	1.6	23
92	Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2019, 16, 81-97.	3.2	91
93	Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2019, 38, 690-698.	1.1	7
94	Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2019, 6, 995-1010.	3.7	306
95	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , 2019, 6, e831-e859.	2.1	341
96	Parental supply of alcohol as a predictor of adolescent alcohol consumption patterns: A prospective cohort. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107529.	1.6	14
97	The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Lancet Public Health</i> , 2019, 4, e334-e342.	4.7	29
98	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 70, 87-93.	1.6	16
99	Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis. <i>Addiction</i> , 2019, 114, 1738-1750.	1.7	32
100	Alcohol Use Disorders in ICD-11: Past, Present, and Future. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1617-1631.	1.4	83
101	Alcohol and parenthood: An integrative analysis of the effects of transition to parenthood in three Australasian cohorts. <i>Drug and Alcohol Dependence</i> , 2019, 197, 326-334.	1.6	28
102	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 435-444.	3.7	145
103	Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys. <i>Addiction</i> , 2019, 114, 1446-1459.	1.7	27
104	Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 708.	6.0	27
105	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	0.9	12
106	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. <i>Journal of Infectious Diseases</i> , 2019, 220, 78-90.	1.9	29
107	Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007–2015. <i>Drug and Alcohol Review</i> , 2019, 38, 159-168.	1.1	0
108	Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. <i>Pain Reports</i> , 2019, 4, e741.	1.4	18

#	ARTICLE	IF	CITATIONS
109	Longitudinal patterns of amphetamine use from adolescence to adulthood: A latent class analysis of a 20-year prospective study of Australians. <i>Drug and Alcohol Dependence</i> , 2019, 194, 121-127.	1.6	7
110	Exploring Comorbidity Within Mental Disorders Among a Danish National Population. <i>JAMA Psychiatry</i> , 2019, 76, 259.	6.0	374
111	Epidemiology of Substance Use Internationally. <i>Advances in Prevention Science</i> , 2019, , 19-36.	0.3	4
112	The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing. <i>Drug and Alcohol Review</i> , 2018, 37, 546-556.	1.1	13
113	The State of US Health, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1444.	3.8	1,042
114	Association of parental supply of alcohol with adolescent drinking, alcohol-related harms, and alcohol use disorder symptoms: a prospective cohort study. <i>Lancet Public Health</i> , The, 2018, 3, e64-e71.	4.7	61
115	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. <i>International Journal of Drug Policy</i> , 2018, 54, 18-25.	1.6	46
116	The associations between psychotic experiences and substance use and substance use disorders: findings from the World Health Organization World Mental Health surveys. <i>Addiction</i> , 2018, 113, 924-934.	1.7	56
117	Accurate identification of opioid overdose deaths using coronial data. <i>Forensic Science International</i> , 2018, 287, 40-46.	1.3	13
118	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. <i>Pain Medicine</i> , 2018, 19, 533-540.	0.9	32
119	To what extent do data from pharmaceutical claims underâ€estimate opioid analgesic utilisation in Australia?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 550-555.	0.9	35
120	Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. <i>Drug and Alcohol Review</i> , 2018, 37, S203-S205.	1.1	32
121	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and metaâ€analysis. <i>Addiction</i> , 2018, 113, 545-563.	1.7	242
122	Health and wellbeing of Indigenous adolescents in Australia: a systematic synthesis of population data. <i>Lancet</i> , The, 2018, 391, 766-782.	6.3	100
123	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	6.3	4,989
124	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1923-1994.	6.3	3,269
125	Population and fertility by age and sex for 195 countries and territories, 1950â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1995-2051.	6.3	294
126	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1789-1858.	6.3	8,569



#	ARTICLE	IF	CITATIONS
127	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
128	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. <i>Nature Neuroscience</i> , 2018, 21, 1656-1669.	7.1	490
129	Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. <i>BMJ Open</i> , 2018, 8, e025840.	0.8	17
130	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 887-896.	1.1	5
131	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	0.8	31
132	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , 2018, 5, 464-472.	1.6	12
133	The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Psychiatry, the</i> , 2018, 5, 987-1012.	3.7	885
134	Cannabis use and non-cancer chronic pain – Authors' reply. <i>Lancet Public Health, The</i> , 2018, 3, e469.	4.7	1
135	Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. <i>Drug and Alcohol Dependence</i> , 2018, 188, 304-310.	1.6	4
136	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i> , 2018, 159, 1932-1954.	2.0	321
137	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2018, 191, 145-151.	1.6	18
138	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health, The</i> , 2018, 3, e341-e350.	4.7	172
139	Amphetamine use in the fourth decade of life: Social profiles from a population-based Australian cohort. <i>Drug and Alcohol Review</i> , 2018, 37, 743-751.	1.1	4
140	Adverse adult consequences of different alcohol use patterns in adolescence: an integrative analysis of data to age 30 years from four Australasian cohorts. <i>Addiction</i> , 2018, 113, 1811-1825.	1.7	43
141	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	1.7	685
142	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	1.3	22
143	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. <i>Addiction</i> , 2018, 113, 1768-1774.	1.7	11
144	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005

#	ARTICLE	IF	CITATIONS
145	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591.	0.9	39
146	A systematic review of injecting-related injury and disease among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2017, 171, 39-49.	1.6	163
147	Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	1.1	13
148	A mapping review of take-home naloxone for people released from correctional settings. <i>International Journal of Drug Policy</i> , 2017, 46, 7-16.	1.6	20
149	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	1.7	2
150	Trends in new psychoactive substances from surface and "dark" net monitoring. <i>Lancet Psychiatry</i> , 2017, 4, 16-18.	3.7	15
151	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1192-e1207.	2.9	1,020
152	Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. <i>World Psychiatry</i> , 2017, 16, 299-307.	4.8	160
153	Trends in heroin and pharmaceutical opioid overdose deaths in Australia. <i>Drug and Alcohol Dependence</i> , 2017, 179, 291-298.	1.6	142
154	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1084-1150.	6.3	573
155	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1260-1344.	6.3	1,589
156	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1151-1210.	6.3	3,565
157	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1211-1259.	6.3	5,578
158	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1345-1422.	6.3	1,879
159	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	1.5	158
160	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1423-1459.	6.3	284
161	Estimating the number of adults with severe and persistent mental illness who have complex, multi-agency needs. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 799-809.	1.3	15
162	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1208-e1220.	2.9	334

#	ARTICLE	IF	CITATIONS
163	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	1.6	54
164	Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. <i>BMJ: British Medical Journal</i> , 2017, 357, j1550.	2.4	1,076
165	Illicit Drugs: Patterns of Use, Dependence, and Contribution to Disease Burden in Developed Countries. , 2017, , 134-145.		2
166	The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. <i>PLoS ONE</i> , 2017, 12, e0169575.	1.1	102
167	Estimating the number of people who inject drugs in Australia. <i>BMC Public Health</i> , 2017, 17, 757.	1.2	38
168	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 521-538.	0.9	63
169	A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 733-737.	0.9	322
170	A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 686-692.	1.1	7
171	Global burden of diseases, injuries, and risk factors for young people's health during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2016, 387, 2383-2401.	6.3	710
172	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
173	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	6.3	4,934
174	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	6.3	5,298
175	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	6.3	4,203
176	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
177	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
178	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 1385-1398.	4.6	223
179	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	1.6	11
180	Commentary on Cousins et al . (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment. <i>Addiction</i> , 2016, 111, 83-84.	1.7	1

#	ARTICLE	IF	CITATIONS
181	Concordance of ICD-11 and DSM-5 definitions of alcohol and cannabis use disorders: a population survey. <i>Lancet Psychiatry</i> , 2016, 3, 673-684.	3.7	47
182	The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. <i>Bipolar Disorders</i> , 2016, 18, 440-450.	1.1	426
183	A systematic review and meta-analysis of racial and ethnic disparities in hepatitis C antibody prevalence in United States correctional populations. <i>Annals of Epidemiology</i> , 2016, 26, 570-578.e2.	0.9	8
184	A Cross-National Examination of Differences in Classification of Lifetime Alcohol Use Disorder Between DSM-IV and DSM-5: Findings from the World Mental Health Survey. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1728-1736.	1.4	35
185	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , 2016, 3, e361-e387.	2.1	461
186	Opioid agonist treatment for pharmaceutical opioid dependent people. <i>The Cochrane Library</i> , 2016, , CD011117.	1.5	148
187	Global Burden Of Disease Studies: Implications For Mental And Substance Use Disorders. <i>Health Affairs</i> , 2016, 35, 1114-1120.	2.5	84
188	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. <i>JAMA Pediatrics</i> , 2016, 170, 267.	3.3	479
189	Prevention, early intervention, harm reduction, and treatment of substance use in young people. <i>Lancet Psychiatry</i> , 2016, 3, 280-296.	3.7	296
190	The increasing global health priority of substance use in young people. <i>Lancet Psychiatry</i> , 2016, 3, 251-264.	3.7	378
191	Why young people's substance use matters for global health. <i>Lancet Psychiatry</i> , 2016, 3, 265-279.	3.7	230
192	The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. <i>Injury Prevention</i> , 2016, 22, 3-18.	1.2	898
193	Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. <i>Lancet</i> , 2016, 387, 1672-1685.	6.3	586
194	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
195	Global Priorities for Addressing the Burden of Mental, Neurological, and Substance Use Disorders. , 2016, , 1-27.		23
196	Global Burden of Mental, Neurological, and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. , 2016, , 29-40.		16
197	Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010. , 2016, , 41-65.		24
198	Illicit Drug Dependence. , 2016, , 109-125.		10

#	ARTICLE	IF	CITATIONS
199	The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. <i>PLoS ONE</i> , 2015, 10, e0116820.	1.1	908
200	Potential bias due to outcome-related loss to follow-up in cohort studies on incidence of drug injection: systematic review and meta-analysis. <i>Addiction</i> , 2015, 110, 1247-1257.	1.7	11
201	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622.	1.1	10
202	Global Epidemiology of HIV Among Women and Girls Who Use or Inject Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, S100-S109.	0.9	46
203	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	6.3	4,951
204	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015, 16, 1745-1758.	0.9	78
205	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. <i>Drug and Alcohol Dependence</i> , 2015, 147, 144-150.	1.6	97
206	Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: A 15-year observational cohort study. <i>Drug and Alcohol Dependence</i> , 2015, 148, 213-216.	1.6	11
207	Symptom screening scales for detecting major depressive disorder in children and adolescents: A systematic review and meta-analysis of reliability, validity and diagnostic utility. <i>Journal of Affective Disorders</i> , 2015, 174, 447-463.	2.0	182
208	Sexual identity, same-sex partners and risk behaviour among a community-based sample of young people in Australia. <i>International Journal of Drug Policy</i> , 2015, 26, 153-161.	1.6	11
209	Mortality among older adults with opioid use disorders in the Veteran's Health Administration, 2000–2011. <i>Drug and Alcohol Dependence</i> , 2015, 147, 32-37.	1.6	52
210	The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study. <i>Drug and Alcohol Dependence</i> , 2015, 152, 264-271.	1.6	15
211	How can data harmonisation benefit mental health research? An example of The Cannabis Cohorts Research Consortium. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 317-323.	1.3	20
212	The Pain and Opioids IN Treatment study. <i>Pain</i> , 2015, 156, 231-242.	2.0	104
213	Adolescent substance use and educational attainment: An integrative data analysis comparing cannabis and alcohol from three Australasian cohorts. <i>Drug and Alcohol Dependence</i> , 2015, 156, 90-96.	1.6	82
214	Editorial Commentary: The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015, 61, 1166-1168.	2.9	4
215	Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. <i>Lancet Psychiatry</i> , 2015, 2, 901-908.	3.7	106
216	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. <i>International Journal of Drug Policy</i> , 2015, 26, 950-957.	1.6	42

#	ARTICLE	IF	CITATIONS
217	Excess mortality among opioid-using patients treated with oral naltrexone in Australia. <i>Drug and Alcohol Review</i> , 2015, 34, 90-96.	1.1	18
218	Associations between psychotic symptoms and substance use in young offenders. <i>Drug and Alcohol Review</i> , 2015, 34, 673-682.	1.1	21
219	Estimating service demand for respite care among informal carers of people with psychological disabilities in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 284-292.	0.8	15
220	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	6.3	1,544
221	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	6.3	2,184
222	Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. <i>Biological Psychiatry</i> , 2015, 78, 474-484.	0.7	64
223	Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. <i>Journal of Abnormal Psychology</i> , 2015, 124, 860-877.	2.0	39
224	The Burden Attributable to Mental and Substance Use Disorders as Risk Factors for Suicide: Findings from the Global Burden of Disease Study 2010. <i>PLoS ONE</i> , 2014, 9, e91936.	1.1	335
225	Illicit Drugs. , 2014, , .		0
226	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. <i>BMJ Open</i> , 2014, 4, e004666.	0.8	54
227	Reply. <i>Hepatology</i> , 2014, 59, 733-734.	3.6	1
228	Afghanistan has a sizeable problem with opioid use. <i>The Lancet Global Health</i> , 2014, 2, e557-e558.	2.9	3
229	Imprisonment of opioid-dependent people in New South Wales, Australia, 2000–2012: a retrospective linkage study. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 165-170.	0.8	10
230	The Global Burden of Disease projects: What have we learned about illicit drug use and dependence and their contribution to the global burden of disease?. <i>Drug and Alcohol Review</i> , 2014, 33, 4-12.	1.1	75
231	Response to <i>Hser et al.</i> (2014): The necessity for more and better data on the global epidemiology of opioid dependence. <i>Addiction</i> , 2014, 109, 1335-1337.	1.7	3
232	The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. <i>Addiction</i> , 2014, 109, 1306-1317.	1.7	165
233	A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women. <i>Drug and Alcohol Review</i> , 2014, 33, 499-505.	1.1	3
234	Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 160-164.	0.8	9

#	ARTICLE	IF	CITATIONS
235	Factors associated with the timing and onset of cannabis use and cannabis use disorder: Results from the 2007 Australian National Survey of Mental Health and Well-being. <i>Drug and Alcohol Review</i> , 2014, 33, 555-564.	1.1	44
236	Commentary: Improving the mental health and substance use estimates in the Global Burden of Disease study: strengthening the evidence base for public policy. <i>International Journal of Epidemiology</i> , 2014, 43, 296-301.	0.9	10
237	Examining non-AIDS mortality among people who inject drugs. <i>Aids</i> , 2014, 28, S435-S444.	1.0	32
238	Causes of death in a cohort treated for opioid dependence between 1985 and 2005. <i>Addiction</i> , 2014, 109, 90-99.	1.7	92
239	The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. <i>Lancet, The</i> , 2014, 383, 1404-1411.	6.3	379
240	The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. <i>Drug and Alcohol Dependence</i> , 2014, 137, 36-47.	1.6	126
241	The adverse health effects of chronic cannabis use. <i>Drug Testing and Analysis</i> , 2014, 6, 39-45.	1.6	288
242	The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. <i>Addiction</i> , 2014, 109, 1320-1333.	1.7	308
243	What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. <i>International Journal of Drug Policy</i> , 2014, 25, 53-60.	1.6	145
244	A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. <i>Drug and Alcohol Review</i> , 2014, 33, 115-128.	1.1	41
245	Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1483-1494.	2.9	33
246	Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. <i>Drug and Alcohol Dependence</i> , 2014, 144, 70-77.	1.6	33
247	Young adult sequelae of adolescent cannabis use: an integrative analysis. <i>Lancet Psychiatry, the</i> , 2014, 1, 286-293.	3.7	354
248	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	6.3	786
249	Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 980-1004.	6.3	1,230
250	Complex Health Needs in the Youth Justice System: A Survey of Community-Based and Custodial Offenders. <i>Journal of Adolescent Health</i> , 2014, 54, 521-526.	1.2	40
251	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	1.6	14
252	Mental and Substance Use Disorders in Sub-Saharan Africa: Predictions of Epidemiological Changes and Mental Health Workforce Requirements for the Next 40 Years. <i>PLoS ONE</i> , 2014, 9, e110208.	1.1	102

#	ARTICLE	IF	CITATIONS
253	Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. <i>Harm Reduction Journal</i> , 2013, 10, 11.	1.3	82
254	Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1575-1586.	6.3	4,651
255	Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1564-1574.	6.3	668
256	Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Addiction</i> , 2013, 108, 2152-2165.	1.7	20
257	The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people. <i>Drug and Alcohol Dependence</i> , 2013, 131, 252-257.	1.6	24
258	The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. <i>Addiction</i> , 2013, 108, 124-133.	1.7	183
259	ANKK1, TTC12, and NCAM1 Polymorphisms and Heroin Dependence. <i>JAMA Psychiatry</i> , 2013, 70, 325.	6.0	66
260	Cannabis Use and the Development and Maintenance of Psychosis. , 2013, , 517-524.		1
261	Mitigating the risk of HIV infection with opioid substitution treatment. <i>Bulletin of the World Health Organization</i> , 2013, 91, 148-149.	1.5	36
262	Mortality among people who inject drugs: a systematic review and meta-analysis. <i>Bulletin of the World Health Organization</i> , 2013, 91, 102-123.	1.5	362
263	How did we arrive at burden of disease estimates for mental and illicit drug use disorders in the Global Burden of Disease Study 2010?. <i>Current Opinion in Psychiatry</i> , 2013, 26, 376-383.	3.1	20
264	Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. <i>Hepatology</i> , 2013, 58, 1215-1224.	3.6	263
265	The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. <i>PLoS ONE</i> , 2013, 8, e76635.	1.1	235
266	Global Epidemiology of Mental Disorders: What Are We Missing?. <i>PLoS ONE</i> , 2013, 8, e65514.	1.1	148
267	HIV Due to Female Sex Work: Regional and Global Estimates. <i>PLoS ONE</i> , 2013, 8, e63476.	1.1	127
268	Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 345, e5945-e5945.	3.0	363
269	Cannabis and progression to other substance use in young adults: findings from a 13-year prospective population-based study. <i>Journal of Epidemiology and Community Health</i> , 2012, 66, e26-e26.	2.0	82
270	The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study. <i>BMJ Open</i> , 2012, 2, e001755.	0.8	32



#	ARTICLE	IF	CITATIONS
271	Extent of illicit drug use and dependence, and their contribution to the global burden of disease. <i>Lancet, The</i> , 2012, 379, 55-70.	6.3	1,074
272	Health of the world's adolescents: a synthesis of internationally comparable data. <i>Lancet, The</i> , 2012, 379, 1665-1675.	6.3	408
273	Commentary on Kelly & Hulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. <i>Addiction</i> , 2012, 107, 1825-1826.	1.7	2
274	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2129-2143.	6.3	1,013
275	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2197-2223.	6.3	7,061
276	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2095-2128.	6.3	11,038
277	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2163-2196.	6.3	6,376
278	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2224-2260.	6.3	9,397
279	Transitions from Injection-Drug-Use-Concentrated to Self-Sustaining Heterosexual HIV Epidemics: Patterns in the International Data. <i>PLoS ONE</i> , 2012, 7, e31227.	1.1	37
280	Commentary on Mehta et al. (2012): Natural history of injecting drug use. <i>Addiction</i> , 2012, 107, 359-360.	1.7	1
281	Cross-National Comparisons of Sex Differences in Opportunities to Use Alcohol or Drugs, and the Transitions to Use. <i>Substance Use and Misuse</i> , 2011, 46, 1169-1178.	0.7	28
282	Sex differences amongst dependent heroin users: Histories, clinical characteristics and predictors of other substance dependence. <i>Addictive Behaviors</i> , 2011, 36, 27-36.	1.7	88
283	Mortality among cocaine users: A systematic review of cohort studies. <i>Drug and Alcohol Dependence</i> , 2011, 113, 88-95.	1.6	182
284	What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. <i>Drug and Alcohol Dependence</i> , 2011, 117, 85-101.	1.6	114
285	Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. <i>Drug and Alcohol Dependence</i> , 2011, 118, 265-273.	1.6	62
286	The association between trauma and delusional-like experiences. <i>Psychiatry Research</i> , 2011, 189, 259-264.	1.7	31
287	Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. <i>Lancet, The</i> , 2011, 378, 571-583.	6.3	1,107
288	The association between cannabis use and depression: a review of the evidence. , 2011, , 114-128.		4

#	ARTICLE	IF	CITATIONS
289	Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. <i>Drug and Alcohol Review</i> , 2011, 30, 236-245.	1.1	107
290	The availability, diversion and injection of pharmaceutical opioids in South Asia. <i>Drug and Alcohol Review</i> , 2011, 30, 246-254.	1.1	48
291	Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. <i>Addiction</i> , 2011, 106, 32-51.	1.7	669
292	Opioid dependence latent structure: two classes with differing severity?. <i>Addiction</i> , 2011, 106, 590-598.	1.7	22
293	The increasing mortality burden of liver disease among opioid-dependent people: cohort study. <i>Addiction</i> , 2011, 106, 2186-2192.	1.7	56
294	Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 220-225.	0.8	51
295	The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey. <i>BMC Psychiatry</i> , 2011, 11, 202.	1.1	46
296	Cannabis and the increased incidence and persistence of psychosis. <i>BMJ: British Medical Journal</i> , 2011, 342, d719-d719.	2.4	19
297	Meth/amphetamine use and associated HIV: Implications for global policy and public health. <i>International Journal of Drug Policy</i> , 2010, 21, 347-358.	1.6	152
298	Improving the data to strengthen the global response to HIV among people who inject drugs. <i>International Journal of Drug Policy</i> , 2010, 21, 100-102.	1.6	14
299	Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. <i>Addiction</i> , 2010, 105, 1117-1128.	1.7	485
300	WHAT ARE THE POLICY IMPLICATIONS OF THE EVIDENCE ON CANNABIS USE AND PSYCHOSIS?. <i>Addiction</i> , 2010, 105, 1332-1333.	1.7	5
301	Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. <i>Drug and Alcohol Review</i> , 2010, 29, 318-330.	1.1	141
302	Early Cannabis Use and Estimated Risk of Later Onset of Depression Spells: Epidemiologic Evidence From the Population-based World Health Organization World Mental Health Survey Initiative. <i>American Journal of Epidemiology</i> , 2010, 172, 149-159.	1.6	64
303	Predictors of social anxiety in an opioid dependent sample and a control sample. <i>Journal of Anxiety Disorders</i> , 2010, 24, 49-54.	1.5	17
304	Is ecstasy a drug of dependence?. <i>Drug and Alcohol Dependence</i> , 2010, 107, 1-10.	1.6	115
305	Evaluating the drug use "gateway" theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. <i>Drug and Alcohol Dependence</i> , 2010, 108, 84-97.	1.6	228
306	Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. <i>Addictive Behaviors</i> , 2010, 35, 741-749.	1.7	106

#	ARTICLE	IF	CITATIONS
307	HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. <i>Lancet, The</i> , 2010, 375, 1014-1028.	6.3	629
308	Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. <i>Lancet, The</i> , 2010, 376, 285-301.	6.3	382
309	Naloxone for administration by peers in cases of heroin overdose. <i>Medical Journal of Australia</i> , 2009, 191, 469-469.	0.8	23
310	Estimating The Level of HIV Prevention Coverage, Knowledge and Protective Behavior Among Injecting Drug Users: What Does The 2008 UNGASS Reporting Round Tell Us?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, S132-S142.	0.9	22
311	Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis?. <i>PLoS Medicine</i> , 2009, 6, e1000133.	3.9	41
312	Child maltreatment as a risk factor for opioid dependence: Comparison of family characteristics and type and severity of child maltreatment with a matched control group. <i>Child Abuse and Neglect</i> , 2009, 33, 343-352.	1.3	100
313	A systematic review of research examining benzodiazepine-related mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 93-103.	0.9	87
314	Are adolescents who moderate their cannabis use at lower risk of later regular and dependent cannabis use?. <i>Addiction</i> , 2009, 104, 806-814.	1.7	21
315	Socio-demographic risk factors for alcohol and drug dependence: the 10-year follow-up of the national comorbidity survey. <i>Addiction</i> , 2009, 104, 1346-1355.	1.7	138
316	Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. <i>Addiction</i> , 2009, 104, 1363-1372.	1.7	81
317	Estimating the burden of disease attributable to illicit drug use and mental disorders: what is the Global Burden of Disease 2005 and why does it matter?. <i>Addiction</i> , 2009, 104, 1466-1471.	1.7	20
318	Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. <i>Drug and Alcohol Review</i> , 2009, 28, 583-585.	1.1	17
319	Sociodemographic predictors of transitions across stages of alcohol use, disorders, and remission in the National Comorbidity Survey Replication. <i>Comprehensive Psychiatry</i> , 2009, 50, 299-306.	1.5	83
320	Further evidence of differences in substance use and dependence between Australia and the United States. <i>Drug and Alcohol Dependence</i> , 2009, 100, 258-264.	1.6	25
321	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. <i>Drug and Alcohol Dependence</i> , 2009, 105, 9-15.	1.6	309
322	Mortality among amphetamine users: A systematic review of cohort studies. <i>Drug and Alcohol Dependence</i> , 2009, 105, 1-8.	1.6	93
323	Reprint of "Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base". <i>Addictive Behaviors</i> , 2009, 34, 795-799.	1.7	15
324	Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. <i>Addictive Behaviors</i> , 2009, 34, 526-530.	1.7	53

#	ARTICLE	IF	CITATIONS
325	Adverse health effects of non-medical cannabis use. <i>Lancet, The</i> , 2009, 374, 1383-1391.	6.3	941
326	The Importance of Timing of Transitions for Risk of Regular Smoking and Nicotine Dependence. <i>Annals of Behavioral Medicine</i> , 2008, 36, 87-92.	1.7	54
327	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008, 103, 462-468.	1.7	161
328	Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. <i>Addiction</i> , 2008, 103, 1361-1370.	1.7	158
329	CANNABIS ABUSE AND DEPENDENCE. , 2008, , 117-148.		4
330	Improving targets for the prevention of drug use disorders: Sociodemographic predictors of transitions across drug use stages in the national comorbidity survey replication. <i>Preventive Medicine</i> , 2008, 47, 629-634.	1.6	27
331	Are diagnostic orphans at risk of developing cannabis abuse or dependence?. <i>Drug and Alcohol Dependence</i> , 2008, 92, 86-90.	1.6	23
332	Assessment of cocaine and other drug dependence in the general population: "Gated" versus "ungated" approaches. <i>Drug and Alcohol Dependence</i> , 2008, 93, 227-232.	1.6	35
333	Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. <i>Lancet, The</i> , 2008, 372, 1733-1745.	6.3	1,107
334	Cannabis use and the risk of developing a psychotic disorder. <i>World Psychiatry</i> , 2008, 7, 68-71.	4.8	109
335	Toward a Global View of Alcohol, Tobacco, Cannabis, and Cocaine Use: Findings from the WHO World Mental Health Surveys. <i>PLoS Medicine</i> , 2008, 5, e141.	3.9	629
336	Cannabis-Induced Psychosis among Aboriginal People in the Northwest Territories. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 475-476.	0.9	0
337	Prevalence and correlates of cannabis use in developed and developing countries. <i>Current Opinion in Psychiatry</i> , 2007, 20, 393-397.	3.1	139
338	The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. <i>Psychological Medicine</i> , 2007, 37, 927-934.	2.7	79
339	Hospital separations for cannabis and methamphetamine-related psychotic episodes in Australia. <i>Medical Journal of Australia</i> , 2007, 186, 342-345.	0.8	47
340	Assessing cannabis dependence in community surveys: methodological issues. <i>International Journal of Methods in Psychiatric Research</i> , 2007, 16, 43-51.	1.1	31
341	Case ascertainment of alcohol dependence in general population surveys: "gated" versus "ungated" approaches. <i>International Journal of Methods in Psychiatric Research</i> , 2007, 16, 111-123.	1.1	35
342	Who are the new amphetamine users? A 10-year prospective study of young Australians. <i>Addiction</i> , 2007, 102, 1269-1279.	1.7	37

#	ARTICLE	IF	CITATIONS
343	Suicidal behaviour and associated risk factors among opioid-dependent individuals: a case-control study. <i>Addiction</i> , 2007, 102, 1933-1941.	1.7	93
344	Affective disorders, anxiety disorders and psychological distress in non-drinkers. <i>Journal of Affective Disorders</i> , 2007, 99, 165-172.	2.0	23
345	Substance use, dependence and treatment seeking in the United States and Australia: A cross-national comparison. <i>Drug and Alcohol Dependence</i> , 2006, 81, 149-155.	1.6	80
346	What are the Policy Implications of the Evidence on Cannabis and Psychosis?. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 566-574.	0.9	41
347	Is Cannabis Use a Contributory Cause of Psychosis?. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 556-565.	0.9	105
348	Documenting the heroin shortage in New South Wales. <i>Drug and Alcohol Review</i> , 2006, 25, 297-305.	1.1	21
349	Reasons for Cannabis use in Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 570-574.	1.3	107
350	Effects of a sustained heroin shortage in three Australian States. <i>Addiction</i> , 2005, 100, 908-920.	1.7	121
351	The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. <i>Drug and Alcohol Dependence</i> , 2005, 79, 129-135.	1.6	29
352	Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage" in NSW, Australia. <i>Drug and Alcohol Dependence</i> , 2005, 79, 397-404.	1.6	13
353	Is there a specific "cannabis psychosis"? , 2004, , 89-100.		15
354	Cannabis use and psychotic disorders: an update. <i>Drug and Alcohol Review</i> , 2004, 23, 433-443.	1.1	88
355	Patterns of co-morbidity between alcohol use and other substance use in the Australian population. <i>Drug and Alcohol Review</i> , 2003, 22, 7-13.	1.1	61
356	Exploring the association between cannabis use and depression. <i>Addiction</i> , 2003, 98, 1493-1504.	1.7	470
357	Testing hypotheses about the relationship between cannabis use and psychosis. <i>Drug and Alcohol Dependence</i> , 2003, 71, 37-48.	1.6	242
358	The link between cannabis use and psychosis: furthering the debate. <i>Psychological Medicine</i> , 2003, 33, 3-6.	2.7	34
359	Cannabis use and mental health in young people: cohort study. <i>BMJ: British Medical Journal</i> , 2002, 325, 1195-1198.	2.4	809
360	"Diagnostic orphans" among young adult cannabis users: persons who report dependence symptoms but do not meet diagnostic criteria. <i>Drug and Alcohol Dependence</i> , 2002, 67, 205-212.	1.6	48

#	ARTICLE	IF	CITATIONS
361	Cannabis and psychosis. <i>Current Psychiatry Reports</i> , 2002, 4, 191-196.	2.1	64
362	Cannabis dependence in young adults: an Australian population study. <i>Addiction</i> , 2002, 97, 187-194.	1.7	142
363	Substance use disorders in an Australian community survey. <i>Drug and Alcohol Review</i> , 2002, 21, 275-280.	1.1	6
364	The relationship between cannabis use and other substance use in the general population. <i>Drug and Alcohol Dependence</i> , 2001, 64, 319-327.	1.6	140
365	The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. <i>Psychological Medicine</i> , 2001, 31, 659-668.	2.7	167
366	Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. <i>Addiction</i> , 2001, 96, 1603-1614.	1.7	263
367	Cannabis Use and Psychosis: A Review of Clinical and Epidemiological Evidence. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 26-34.	1.3	160
368	Cohort trends in the age of initiation of drug use in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 421-426.	0.8	105
369	Cohort Trends in Youth Suicide in Australia 1964-1997. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 408-412.	1.3	21
370	Alcohol- and Drug-Use Disorders in Australia: Implications of the National Survey of Mental Health and Wellbeing. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 206-213.	1.3	193
371	The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. <i>Addiction</i> , 1999, 94, 1541-1550.	1.7	145
372	Schizophrenia secondary to cannabis use. , 0, , 169-178.		0
373	Substance Use and Mental Health in Longitudinal Perspective. , 0, , 43-51.		20
374	What are the policy implications of the evidence on cannabis and psychosis?. , 0, , 55-65.		1
375	Drug-Use Disorders. , 0, , 243-262.		3
376	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. <i>Exploration of Medicine</i> , 0, , .	1.5	0